熱門資訊> 正文
Viracta Therapeutics任命Michael Faerm为首席财务官
2024-05-14 19:25
- Viracta Therapeutics (NASDAQ:VIRX) said it has appointed Michael Faerm as its CFO, effective immediately.
- Faerm has more than 25 years of experience in life sciences companies, equity research and investment banking, and was recently the interim finance chief at Harpoon Therapeutics.
More on Viracta Therapeutics
- Day One wins FDA nod for brain cancer therapy, Ojemda
- Viracta slides on lower response rate in trial for lymphoma treatment cohort
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。